当前位置: X-MOL 学术bioRxiv. Microbiol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
bioRxiv - Microbiology Pub Date : 2020-08-04 , DOI: 10.1101/2020.08.03.235291
Sho Iketani 1, 2 , Farhad Forouhar 3 , Hengrui Liu 4 , Seo Jung Hong 5 , Fang-Yu Lin 6 , Manoj S Nair 1 , Arie Zask 7 , Yaoxing Huang 1 , Li Xing 6 , Brent R Stockwell 4, 7 , Alejandro Chavez 5 , David D Ho 1
Affiliation  

We report the identification of three structurally diverse compounds, compound 4, GC376, and MAC-5576, as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.

中文翻译:


用于开发 SARS-CoV-2 3CL 蛋白酶抑制剂的先导化合物。



我们报告了三种结构不同的化合物的鉴定,即化合物 4、GC376 和 MAC-5576,它们是 SARS-CoV-2 3CL 蛋白酶的抑制剂。这些与蛋白酶复合的化合物的结构揭示了进一步开发的策略,以及设计 SARS-CoV-2 3CL 蛋白酶抑制剂的一般原则。因此,这些化合物可以作为构建有效的 SARS-CoV-2 3CL 蛋白酶抑制剂的基础的先导化合物。
更新日期:2020-08-05
down
wechat
bug